FAIRY: a randomized controlled patient-blind phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) to placebo in patients with acute isovolemic anemia after gastrectomy - study protocol for a randomized controlled trial

Daniel Reim, Young-Woo Kim, Byung Ho Nam, Mi-Jung Kim, Jeong Hwan Yook, Young Kyu Park, Sung Hoon Roh, Wan Sik Yu, Jae Moon Bae, Daniel Reim, Young-Woo Kim, Byung Ho Nam, Mi-Jung Kim, Jeong Hwan Yook, Young Kyu Park, Sung Hoon Roh, Wan Sik Yu, Jae Moon Bae

Abstract

Background: Isovolemic anemia (decrease in hemoglobin concentration with normal or even increased blood volume) after gastric cancer surgery may negatively influence short- and long-term outcomes. Therefore correction of isovolemic postoperative anemia is supposed to be beneficial. This prospective randomized placebo-controlled multicenter trial is designed to evaluate the efficacy of ferric carboxymaltose administration with the primary end point of successful hemoglobin level increase by 2 g/dl at 12 weeks after randomization.

Methods and design: Gastric cancer patients after oncologic resection and postoperative hemoglobin level ≥ 7 g/dl to <10 g/dl at postoperative days 5 to 7 will be eligible for trial inclusion. After randomization, 450 patients (225 per group) are going to be subjected either to administration of ferric carboxymaltose (treatment group) or normal (0.9%) saline (placebo group). Patients will be blinded to the intervention. Patients will undergo evaluation for hemoglobin level, hematology and quality of life assessment 3 and 12 weeks after randomization.

Discussion: Correction of isovolemic postoperative anemia in gastric cancer patients after oncologic resection is considered to be beneficial. Administration of ferric carboxymaltose is considered to be superior to placebo for anemia correction without the possible risks of red blood cell transfusion. Further, improved quality of life for patients with quick recovery of hemoglobin levels is expected.

Trial registration: NCT01725789 (international: http://www.clinicaltrials.gov) and NCCCTS-12-644 (NCC, Korea).

Figures

Figure 1
Figure 1
Study scheme of FAIRY trial, inclusion/exclusion criteria, intervention, and end points.

References

    1. Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med. 2004;Suppl 7A:58S–69S.
    1. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion. 2007;47:1468–1480. doi: 10.1111/j.1537-2995.2007.01286.x.
    1. Weiskopf RB, Kramer JH, Viele M, Neumann M, Feiner JR, Watson JJ, Hopf HW, Toy P. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology. 2000;92:1646–1652. doi: 10.1097/00000542-200006000-00023.
    1. Weiskopf RB, Feiner J, Hopf HW, Viele MK, Watson JJ, Kramer JH, Ho R, Toy P. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. Anesthesiology. 2002;96:871–877. doi: 10.1097/00000542-200204000-00014.
    1. Jung DH, Lee HJ, Han DS, Suh YS, Kong SH, Lee KU, Yang HK. Impact of perioperative hemoglobin levels on postoperative outcomes in gastric cancer surgery. Gastric Cancer. 2013;16:377–382. doi: 10.1007/s10120-012-0196-8.
    1. Liang YX, Guo HH, Deng JY, Wang BG, Ding XW, Wang XN, Zhang L, Liang H. Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World J Gastroenterol. 2013;19:5542–5550. doi: 10.3748/wjg.v19.i33.5542.
    1. Adachi Y, Mimori K, Mori M, Maehara Y, Sugimachi K. Morbidity after D2 and D3 gastrectomy for node-positive gastric carcinoma. J Am Coll Surg. 1997;184:240–244.
    1. Weber RS, Jabbour N, Martin RC 2nd. Anemia and transfusions in patients undergoing surgery for cancer. Ann Surg Oncol. 2008;15:34–45. doi: 10.1245/s10434-007-9502-9.
    1. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med. 2007;131:708–718.
    1. Wu HS, Little AG. Perioperative blood transfusions and cancer recurrence. J Clin Oncol. 1988;6:1348–1354.
    1. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1 CD005033.
    1. Kneuertz PJ, Patel SH, Chu CK, Maithel SK, Sarmiento JM, Delman KA, Staley CA 3rd, Kooby DA. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol. 2011;18:1327–1334. doi: 10.1245/s10434-010-1476-3.
    1. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, Chen CL. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2009;16:1832–1842. doi: 10.1245/s10434-009-0448-y.
    1. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599–1607. doi: 10.1093/ndt/gfq613.
    1. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M. Anaemia Working Group España. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patientsundergoing major elective surgery. Br J Anaesth. 2011;107:477–478. doi: 10.1093/bja/aer242.
    1. Yoon HM, Kim YW, Nam BH, Reim D, Eom BW, Park JY, Ryu KW. Intravenous iron supplementation may be superior to observation in acute isovolemic post-gastrectomy anemia. World J Gastroenterol. 2014;20:1582–1857. doi: 10.3748/wjg.v20.i6.1582.
    1. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895. doi: 10.1002/cncr.10763.
    1. Sobin LH, Wittekind C, editor. UICC. TNM classification of malignant tumours. 7. New York, NY: Wiley-Liss; 2010.
    1. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley & Sons Ltd; 1983.
    1. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR. American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28:4996–5010. doi: 10.1200/JCO.2010.29.2201.
    1. Evstatiev R, Marteau P, Iqbal T. FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846–853. doi: 10.1053/j.gastro.2011.06.005.
    1. Lim CH, Kim SW, Kim WC, Kim JS, Cho YK, Park JM, Lee IS, Choi MG, Song KY, Jeon HM, Park CH. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. World J Gastroenterol. 2012;18:6114–6119. doi: 10.3748/wjg.v18.i42.6114.
    1. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448. doi: 10.1056/NEJMoa0908355.
    1. Pfenniger A, Schuller C, Christoph P, Surbek D. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med. 2012;40:397–402.
    1. Park SH, Nam E, Bang SM, Cho EK, Shin DB, Lee JH. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer. Cancer Chemother Pharmacol. 2008;62:1–9. doi: 10.1007/s00280-007-0561-1.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit